High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy

被引:118
作者
Bartlett, Edmund K. [1 ]
Flynn, Jessica R. [2 ]
Panageas, Katherine S. [2 ]
Ferraro, Richard A. [1 ]
Sta Cruz, Jessica M. [1 ]
Postow, Michael A. [3 ]
Coit, Daniel G. [1 ]
Ariyan, Charlotte E. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA
关键词
checkpoint inhibitor; melanoma; neutrophil-to-lymphocyte ratio; PD-1; inhibitor; PERIPHERAL-BLOOD; METASTATIC MELANOMA; IMMUNOTHERAPY; IPILIMUMAB; NIVOLUMAB; SURVIVAL; OUTCOMES; DISEASE; COUNTS;
D O I
10.1002/cncr.32506
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background An elevated neutrophil-to-lymphocyte ratio (NLR) is associated with poor survival in patients with cancer, including those who receive immunotherapies. The authors sought to investigate NLR as a biomarker of treatment outcomes in patients with melanoma who were treated with PD-1 inhibition. Methods Patients undergoing initial treatment with PD-1 inhibitor monotherapy for stage IV melanoma at a single center from 2012 to 2015 were included. Clinical characteristics and the NLR at baseline and before subsequent treatment cycles were collected. The time to treatment failure (TTF) and overall survival (OS) were evaluated using Kaplan-Meier and landmark analyses. Results Among 224 study patients, 63 (28%) had a baseline NLR >= 5. The baseline NLR was significantly associated with Eastern Cooperative Oncology Group performance status and the number of involved metastatic sites. With a median follow-up of 39 months in survivors, a baseline NLR >= 5 was independently associated with shorter OS (hazard ratio, 2.0; 95% CI, 1.3-2.9) and TTF (hazard ratio, 1.7; 95% CI, 1.2-2.4). An NLR increase >= 30% during the first 2 cycles of treatment was associated with worse OS (median, 47 vs 13.5 months;P < .001) and a trend toward shorter TTF (12.8 vs 5.9 months;P = .05). A combined baseline NLR >= 5 and an NLR increase >= 30% identified a small cohort with markedly shortened OS (median, 5.8 months) and TTF (median, 1.8 months). Conclusions Elevated baseline NLR and an increased NLR early during treatment are prognostic for TTF and OS in patients who have melanoma treated with PD-1 inhibitor monotherapy. Combined, these biomarkers can widely risk-stratify patients for treatment failure and survival.
引用
收藏
页码:76 / 85
页数:10
相关论文
共 32 条
[1]   Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer [J].
Bagley, Stephen J. ;
Kothari, Shawn ;
Aggarwal, Charu ;
Bauml, Joshua M. ;
Alley, Evan W. ;
Evans, Tracey L. ;
Kosteva, John A. ;
Ciunci, Christine A. ;
Gabriel, Peter E. ;
Thompson, Jeffrey C. ;
Stonehouse-Lee, Susan ;
Sherry, Victoria E. ;
Gilbert, Elizabeth ;
Eaby-Sandy, Beth ;
Mutale, Faith ;
DiLullo, Gloria ;
Cohen, Roger B. ;
Vachani, Anil ;
Langer, Corey J. .
LUNG CANCER, 2017, 106 :1-7
[2]   Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis [J].
Benedict Sacdalan, Danielle ;
Anne Lucero, Josephine ;
Lee Sacdalan, Dennis .
ONCOTARGETS AND THERAPY, 2018, 11 :955-965
[3]   Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis [J].
Bowen, Randy C. ;
Little, Nancy Ann B. ;
Harmer, Joshua R. ;
Ma, Junjie ;
Mirabelli, Luke G. ;
Roller, Kyle D. ;
Breivik, Andrew Mackay ;
Signor, Emily ;
Miller, Alec B. ;
Khong, Hung T. .
ONCOTARGET, 2017, 8 (19) :32171-32189
[4]   Surgical Management of Intraabdominal Metastases From Melanoma: Role of the Neutrophil to Lymphocyte Ratio as a Potential Prognostic Factor [J].
Cananzi, Ferdinando C. M. ;
Dalgleish, Angus ;
Mudan, Satvinder .
WORLD JOURNAL OF SURGERY, 2014, 38 (06) :1542-1550
[5]   Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab [J].
Capone, Mariaelena ;
Giannarelli, Diana ;
Mallardo, Domenico ;
Madonna, Gabriele ;
Festino, Lucia ;
Grimaldi, Antonio Maria ;
Vanella, Vito ;
Simeone, Ester ;
Paone, Miriam ;
Palmieri, Giuseppe ;
Cavalcanti, Ernesta ;
Caraco, Corrado ;
Ascierto, Paolo Antonio .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[6]   Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment [J].
Cassidy, Michael R. ;
Wolchok, Rachel E. ;
Zheng, Junting ;
Panageas, Katherine S. ;
Wolchok, Jedd D. ;
Coit, Daniel ;
Postow, Michael A. ;
Ariyan, Charlotte .
EBIOMEDICINE, 2017, 18 :56-61
[7]   Fuhrman Grade and Neutrophil-To-Lymphocyte Ratio Influence on Survival in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors [J].
Chrom, Pawel ;
Stec, Rafal ;
Semeniuk-Wojtas, Aleksandra ;
Bodnar, Lubomir ;
Spencer, Nathaniel J. ;
Szczylik, Cezary .
CLINICAL GENITOURINARY CANCER, 2016, 14 (05) :457-464
[8]   Neutrophils in cancer: neutral no more [J].
Coffelt, Seth B. ;
Wellenstein, Max D. ;
de Visser, Karin E. .
NATURE REVIEWS CANCER, 2016, 16 (07) :431-446
[9]   Elevated Blood Neutrophil-to-Lymphocyte Ratio: A Readily Available Biomarker Associated with Death due to Disease in High Risk Nonmetastatic Melanoma [J].
Davis, Jeremy L. ;
Langan, Russell C. ;
Panageas, Katherine S. ;
Zheng, Junting ;
Postow, Michael A. ;
Brady, Mary S. ;
Ariyan, Charlotte ;
Coit, Daniel G. .
ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (07) :1989-1996
[10]   A peripheral blood biomarker estimates probability of survival: the neutrophil-lymphocyte ratio in noncancer patients [J].
Davis, Jeremy L. ;
Moutinho, Vitor, Jr. ;
Panageas, Katherine S. ;
Coit, Daniel G. .
BIOMARKERS IN MEDICINE, 2016, 10 (09) :953-957